SURFACTANT
RESEARCH

NOVEMBER 30 – DECEMBER 4, 2020

Clarifying the surfactant role in neonates,
children and adults with respiratory failure

MONDAY – NOVEMBER 30, 2020

PreClinical
Session 1
13:30 – 15:45

How can we enhance surfactant efficiency?
Chairs: D. De Luca, L. Touqui (Paris, France)

13:30 – 14:00
Greetings: Daniele De Luca (MD, PhD), Fabrizio Salomone (PhD)
14:00 – 14:15
The role of budesonide – N. Hillman (St.Louis, MO – USA)
15 min discussion
14:30 – 14:45
The role of varespladib and sPLA2 inhibitors – G. Lambeau (Nice, France)
15 min discussion
15:00 – 15:15
The role of DOPG – M. F. Krause (Kiel, Germany)
15 min discussion
15:30 – 15:45
The role of hu-r-SP-D – P. Kingma (Cincinnati, OH – USA)
15 min discussion
Clinical
Session 1
17:00 – 18:15

How to study surfactant effect on the bedside in PICU/NICU?
Chair: P.Rimensberger (Geneve, Switzerland)

17:00 – 17:15
EIT – A. van Kaam (Amsterdam, Netherlands)
15 min discussion
17:30 – 17:45
Lung ultrasound – D. De Luca (Paris, France)
15 min discussion
18:00 – 18:15
Lung MRI – P. Kingma (Cincinnati, OH – USA)
15 min discussionr

TUESDAY – DECEMBER 1, 2020

Clinical
Session 2
14:00 – 16:15

Are there alternative way to deliver surfactant?
Chair: A. van Kaam (Amsterdam, Netherlands)

14:00 – 14:15
Non-bronchoscopic bronchoalveolar lavage – D. Tingay (Melbourne, Australia)
15 min discussion
14:30 – 14:45
Bronchoscopic broncho-alveolar lavage – P. Biban (Verona, Italy)
15 min discussion
15:00 – 15:45
Supraglottic devices – D. Trevisanuto (Padua, Italy)
15 min discussion
16:00 – 16:15
Nebulization – F. Bianco (Parma, Italy)
15 min discussion
PreClinical
Session 2
17:00 – 18:50

Open questions in surfactant biology
Chair: G. Lambeau (Nice, France)

17:00 – 17:20
What is the interaction between surfactant and secretory phospholipases? – D. Hite (Cincinnati, OH – USA)
10 min discussion
17:30 – 17:50
What is the best animal model to study surfactant injury? – F. Salomone (Parma, Italy)
10 min discussion
18:00 – 18:20
Can surfactant really be a drug carrier? – J. Perez-Gil (Madrid, Spain)
10 min discussion
18:30 – 18:50
Can we distinguish between endogenous and exogenous surfactant metabolism? – V. P. Carnielli (Ancona, Italy)
10 min discussion

WEDNESDAY – DECEMBER 2, 2020

PreClinical
Session 3
14:00 – 16:20

What is what in surfactant biology?
Chair: E. Lopez-Rodriguez (Hannover, Germany)

14:00 – 14:20
cPLA2 or sPLA2? What is the most important phospholipase in lung injury? – M. Murakami (Tokyo, Japan)
10 min discussion
14:30 – 14:50
What is the effect of oxidative stress on surfactant? – M. Vento (Valencia, Spain)
10 min discussion
15:00 – 15:20
What may be the best surfactant composition? – J. Perez-Gil (Madrid, Spain)
10 min discussion
16:00 – 16:20
What is the effect of hypothermia on surfactant? – D. De Luca (Paris, France)
10 min discussion
Clinical
Session 3
17:00 – 18:20

Surfactant and ARDS
Chair: MV. Ranieri (Bologna, Italy)

17:00 – 17:20
Epithelial and surfactant damage in various types of ARDS – C. Calfee (San Francisco, CA- USA)
10 min discussion
17:30 – 17:50
Surfactant composition changes in ARDS – A. Gunther (Giessen, Germany)
10 min discussion
18:00 – 18:20
Future directions for surfactant therapy in NARDS and PARDS – D. De Luca (Paris, France)
10 min discussion

THURSDAY – DECEMBER 3, 2020

PreClinical
Session 4
14:00 – 15:45

Bedside biological test to evaluate surfactant status
Chair: F. Salomone (Parma, Italy)

14:00 – 14:15
Spectroscopic lipid analysis – H. Verder (Holbaek, Denmark)
15 min discussion
14:30 – 14:45
Surfactant adsorption test – C. Autilio (Madrid, Spain)
15 min discussion
15:00 – 15:15
Lamellar body count – D. De Luca (Paris, France)
15 min discussion
15:30 – 15:45
Stable microbubble test – H. Fiori (Porto Alegre, Brasil)
15 min discussion
Clinical
Session 4
17:00 – 18:50

ARDS: Surfactant system as biomarker
Chair: M. Lewin (Corte Madera, CA – USA)

17:00 – 17:20
Phospholipases as biomarkers for ARDS – M. Lekka (Ioannina, Greece)
10 min discussion
17:30 – 17:50
Surfactant proteins as biomarker for ARDS – M. D. Eisner (San Francisco, CA – USA)
10 min discussion
18:00 – 18:20
Surfactant proteins as biomarker for PARDS – H. Flori (Ann Arbor, MI – USA)
10 min discussion
18:30 – 18:50
Biomarker for ARDS or biomarker for VILI in ARDS patients? – MV. Ranieri (Bologna, Italy) 10 min discussion

FRIDAY – DECEMBER 4, 2020

Clinical
Session 5
14:00 – 15:20

Compassionate surfactant therapies in ARDS
Chair: D. De Luca (Paris, France)

14:00 – 14:20
Use of surfactant therapies for NARDS – D. Tingay (Melbourne, Australia)
10 min discussion
14:30 – 14:50
Use of surfactant therapies for PARDS – M. Piastra (Rome, Italy)
10 min discussion
15:00 – 15:20
Use of surfactant for ARDS – S. Busoni (Modena, Italy)
10 min discussion
PreClinical
Session 5
16:30 – 18:10

Is there a role for surfactant in COVID19?
Chair: M. Antonelli (Rome, Italy)

16:30 – 16:50
COVID19 is not (always) a “real” ARDS – M. Cecconi (Milan, Italy)
10 min discussion
17:00 – 17:20
What really is respiratory failure due to COVID19? – G. Iotti (Pavia, Italy)
10 min discussion
17:30 – 17:50
What really is COVID19 in PICU? – P. Tissieres (Paris, France)
10 min discussion
18:00 – 18:10
Closing remarks: Daniele De Luca (MD, PhD)

ORGANIZED BY:

Daniele De Luca (MD, PhD)
France

ENDORSED BY

Scientific Committee

Massimo Antonelli
Roma, Italy

Giorgio Conti
Roma, Italy

Heide Flori
Ann Arbor – MI, USA

Anton van Kaam
Amsterdam, Netherlands

Gerard Lambeau
Nice, France

Salvatore M. Maggiore
Pescara, Italy

Pierre Tissieres
Paris, France

David Tingay
Melbourne, Australia

Ram Ramanatham
Los Angeles – CA, USA

JOIN THE CONGRESS!

JOIN THE CONGRESS!

Keep Yourself
Posted!

Subscribe to the Congress Newsletter!